US 9186357

I'll search for authoritative current information on this patent, including any 2026 litigation developments.

Let me search for the specific IPR proceedings and any Federal Circuit docket activity.

Let me verify the full claim set and check for any appellate activity.

US 9,186,357 B2 — Summary

I searched for this specific number only. Below, each identifier is transcribed literally as it appears in the sources. Where I could not obtain authoritative text, I say so.

Bibliographic data (high confidence)

Abstract (verbatim): "Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery."

Note: an assignment record also lists Riccardo Braglia as an assignor alongside the five named inventors. A security interest recorded to Hamilton SA LLC (2022‑12‑30) was released back to Helsinn and affiliates on 2023‑09‑20.

Plain-language overview of the independent claims

The subject matter is a drug regimen for chemotherapy‑induced nausea and vomiting (CINV) built around the NK₁ antagonist netupitant (Helsinn's drug, later marketed as AKYNZEO together with palonosetron). The independent claims I could verify from the patent text and the IPR petition are:

• Claim 1 — A method of treating CINV by administering to a chemotherapy patient a regimen of palonosetron, netupitant and dexamethasone (all three together). This is the broadest capture‑the‑combination claim.
• Claim 2 — A method of treating CINV in a chemotherapy patient by administering a regimen of netupitant and a sub‑therapeutic dose of dexamethasone (dexamethasone at a dose that would be ineffective alone but works because netupitant potentiates it). Claim 3, depending on it, defines the sub‑therapeutic dose as about 50–70% of the minimum effective dose.
• Claim 4 — A method of treating CINV by inducing blood levels of palonosetron and netupitant effective to treat the CINV (a "blood‑level" style claim rather than a step‑by‑step administration claim).

Claims 5–18 and 19–39 are dependents of these, adding chemotherapy types (e.g., cisplatin, carboplatin, oxaliplatin, doxorubicin, cyclophosphamide), dosing (netupitant ~300 mg free base; palonosetron ~0.50 mg HCl; dexamethasone ~12 mg day 1 and ~8 mg days 2–4), timing (no more than 1–2 hours before chemotherapy), five‑day single‑administration regimens, receptor‑occupancy limits (≥70% striatum NK₁ occupancy at 96 hours), and a "no emetic episodes / no rescue medication" definition of treatment.

Uncertainty flagged: The full text I could retrieve cut off at claim 16, and the IPR petition lists the challenged set as claims 1, 5–10, 17–39 and 43–51, indicating there are further claims (43–62) I have not read verbatim. Given the specification's emphasis on a hard‑shell capsule housing a palonosetron soft‑gel and netupitant tablets, those unshown claims likely include additional independent dosage‑form/combination claims, but I am not asserting that without the text.

Litigation / PTAB status (2026)

• The patent is Orange Book‑listed for AKYNZEO (NDA 205718, netupitant/palonosetron, approved 2014‑10‑10), with use codes listed variously as U‑528, U‑2293 and U‑2301; it is also listed against the IV fosnetupitant product (NDA 210493).
• Inter partes reviews are active. Docket records show Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A., PTAB IPR2025‑00946 and IPR2025‑00947, both filed 2025‑05‑01 and directed to U.S. Patent 9,186,357. The board granted institution on 2025‑11‑19 in IPR2025‑00947. The petitioner's grounds rely on references including Herrstedt, Bös (US 6,297,375), Herrington, and the ALOXI label, and also involve related Helsinn patents 8,623,826; 9,943,515; and 10,828,297. Helsinn has argued synergy between netupitant and palonosetron as the basis for patentability.
• No Federal Circuit docket for 9,186,357 surfaced in my searches. Any appeal would ordinarily follow a final written decision (not yet reached in these 2025‑instituted IPRs), so a 2026 CAFC appeal of this patent appears not to exist yet. I found no CAFC 2026 case naming this patent number.
• Historically, this patent was asserted in New Jersey District Court litigation (cases listed as 3:22‑cv‑04635 and 2:22‑cv‑04635).

Caveats

• I could not independently confirm the full text of claims 43–62, nor a complete, authoritative final claim count beyond the 62 stated on the patent front page.
• Docket sources I retrieved carry "last updated" dates spanning mid‑2026; I treated these as the most current available. If you need a certified current PTAB/Federal Circuit status, the USPTO PatentCenter and PACER dockets should be checked directly, since litigation status changes frequently.

I'll research litigation involving US patent 9186357. Let me search multiple sources.

Let me dig deeper on the PTAB proceedings and the district court case details.

Let me verify the PTAB institution status and check for any other cases or appeals.

Litigation Involving U.S. Patent No. 9,186,357 ("the '357 patent")

Patent: U.S. 9,186,357 B2 — "Compositions and methods for treating centrally mediated nausea and vomiting" (Helsinn Healthcare SA; priority 2009-11-18; granted 2015-11-17; Orange Book listed against AKYNZEO, U-2301). Note: the '357 patent is the Orange Book-listed use patent for Akynzeo (netupitant/palonosetron), not the earlier palonosetron-injection (ALOXI) patents.

I identified one district court case and one set of PTAB proceedings specifically involving U.S. 9,186,357.

1. District Court — Helsinn Healthcare S.A. v. Gland Pharma Limited

Sources:

• Complaint (Doc. 1) naming the '357 patent: https://www.courtlistener.com/docket/63601016/1/helsinn-healthcare-sa-v-gland-pharma-limited/
• Consent Judgment / dismissal: https://paragraphfour.com/wp-content/uploads/2022/07/njdc22cv4635CJ.pdf and https://www.courtlistener.com/docket/63601016/50/helsinn-healthcare-sa-v-gland-pharma-limited/
• DrugPatentWatch docket summary: https://www.drugpatentwatch.com/p/litigation/casename/index.php?query=HELSINN+HEALTHCARE+S.A.+v.+GLAND+PHARMA+LIMITED%7c3%3a22-cv-04635

⚠️ Caveat on the dismissal language: Docket sources are internally inconsistent. One entry states the claims were dismissed "with prejudice"; the Consent Judgment text states claims were dismissed "without prejudice." The parties also waived any right to appeal. I cannot resolve the discrepancy with certainty from the available records, so treat the precise prejudice term as unconfirmed.

2. PTAB — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A. (Inter Partes Review)

Sources:

• IPR2025-00946 (Patent 9,186,357 B2): https://ipverse.greyb.com/ptab-web/cases/case-details/IPR2025-00946
• IPR2025-00947 mandatory notices (Patent 9,186,357): https://gaeflexstaging-dot-docketupdate.appspot.com/cases/PTAB/IPR2025-00947/AZURITY_PHARMACEUTICALS_INC._v._Helsinn_Healthcare_S.A/05-22-2025-Patent_Owner/Notice__Mandatory_Notice-5-Patent_Owners_Mandatory_Notices/
• Director Discretionary Decision Refer (Sept. 19, 2025): https://gaeflexstaging-dot-docketupdate.appspot.com/cases/PTAB/IPR2025-00946/.../09-19-2025-Board/Director_Discretionary_Decision_Refer-12-Director_Discretionary_Decision_Refer/

Related proceedings (same petitioner, same day): An exhibit references sister IPRs IPR2025-00945, -00946, -00947, -00948, and -00949, suggesting Azurity filed a coordinated set of petitions against several Helsinn patents. The '357 patent is challenged in the -946 and -947 proceedings specifically.

Note on conflicting party attribution: The Google Patents family/litigation metadata for this patent labels the PTAB petitioner field with the attribution string "Unified Patents PTAB Data." That is a data-source citation (from the Unified Patents PTAB dataset), not the identity of the petitioner. The actual petitioner, per the PTAB filings themselves, the Patent Owner mandatory notices, IPVerse, Docket Alarm, and DrugPatentWatch, is Azurity Pharmaceuticals, Inc. I am flagging this because the Google Patents page could otherwise be misread as naming "Unified Patents" as the petitioner.

3. Federal Circuit (CAFC)

I did not find (and could not complete verification of) any Court of Appeals for the Federal Circuit appeal specifically involving the '357 patent. Because the New Jersey case settled under a consent judgment with a waiver of appeal, no CAFC appeal would be expected from that case. Whether either IPR has been appealed cannot be confirmed — my verification searches were cut short. Treat any CAFC activity as unconfirmed.

4. Other Helsinn Litigation — Scope Limitation

Helsinn has been involved in extensive palonosetron/ALOXI and Akynzeo patent litigation (e.g., against Teva, Dr. Reddy's, Sandoz, Sagent, Hospira, Actavis, Fresenius Kabi, and others — see e.g. D.N.J. 3:13-cv-05815, 3:15-cv-02077, 3:16-cv-01683). However, those cases asserted different patents (e.g., the palonosetron injection patents U.S. 7,947,724 / 7,947,725 / 7,960,424 / 8,598,219 / 8,729,094 and the ALOXI-related '450/'586 patents). I did not find the '357 patent asserted in any district court case other than the Gland Pharma action above. I cannot rule out additional ANDA suits asserting the '357 patent that I did not surface.

Summary

• District court litigation asserting U.S. 9,186,357: 1 known case — Helsinn Healthcare S.A. v. Gland Pharma Limited, D.N.J. No. 3:22-cv-04635, filed July 18, 2022; settled via consent judgment, case closed (Dec. 2022 / Jan. 2023).
• PTAB litigation involving U.S. 9,186,357: Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A., IPR2025-00946 and IPR2025-00947, filed May 1, 2025; pending/instituted.
• CAFC: none confirmed.
• Other cases against the '357 patent: none identified.

Confidence: High for the two proceedings above (multiple corroborating sources, including primary PTAB filings and the court docket). Medium regarding absence of other cases, given that my verification searches were truncated and Helsinn's overall litigation campaign is broad. All case numbers, dates, and party names are reported exactly as found; I have not auto-corrected any identifier.

I'll start by reconciling the two structured sources in the prompt — the ODP ingest says no proceedings, but the patent-page litigation block already names two PTAB cases — then verify with web search.

The petitioner is Azurity Pharmaceuticals (not Unified Patents — that's the data-source attribution). Let me pin down the institution decisions, grounds, and claims for both IPRs.

Now let me pin down IPR2025-00946's challenged claims and grounds, plus any parallel district court / appeal activity.

PTAB proceedings overview

Two AIA trial proceedings are on file against US 9,186,357 — both inter partes reviews filed 2025-05-01 by Azurity Pharmaceuticals, Inc. against Helsinn Healthcare S.A., both instituted on 2025-11-19, and both still in trial as of 2026-09-17. No claims have been canceled, no final written decision has issued, and no appeal has been taken — so the patent currently stands intact, but the two petitions together challenge all 62 claims, meaning a defendant today faces a patent under full-scale, live PTAB attack with a decision due in roughly two months.

Two flags on the source data. (1) The structured "PTAB proceedings on file" block states the ODP API returns no AIA trial proceedings. That is stale — Google Patents' own litigation block on the same page, plus Unified Patents' PTAB portal, Docket Alarm and PTAB petitions on PTACTS, all confirm IPR2025-00946 and IPR2025-00947 were filed 2025-05-01 and instituted 2025-11-19. I treat the ODP field as an ingest lag, not as authority that no proceedings exist. (2) The Google Patents litigation block labels the petitioner field "Unified Patents PTAB Data." That is the data-source attribution, not the filer. The petitioner is Azurity Pharmaceuticals, Inc. There is no Unified Patents (defensive aggregator) filing in this chain — that matters for the pattern-signal analysis below.

IPR2025-00947 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.

• Type: Inter Partes Review (pre-AIA § 103 — the patent has a 2009-11-18 priority date, so pre-AIA statutory framing applies; Applicant admitted this expressly in the petition: "All references to §§102 and 103 are to the pre-AIA versions.")

• Filed: 2025-05-01

• Status: Trial Instituted (verbatim: "Trial Instituted" / "Instituted," per Docket Alarm and the Google Patents litigation block: "PTAB case IPR2025-00947 filed (Pending - Instituted)"). Plain English: the Board found a reasonable likelihood of prevailing on at least some challenged claims and put the case on a one-year trial clock. Not yet decided on the merits.

• Judge panel: Michael J. Fitzpatrick, Sheridan K. Snedden, Christopher G. Paulraj (APJs)

• Petition grounds: Challenges claims 1, 5-10, 17-39, and 43-51 (39 claims, including independent claim 1) under pre-AIA § 103. Ground 4 is expressly omitted from this petition ("ground 4 is omitted from this IPR"). The petition's ground table:

  Ground	Claims	Art
  1	1, 5-10, 17	Herrstedt & Bös
  2	18-19, 25-27, 30-32	Herrstedt, Bös & Herrington
  3	20	Herrstedt, Bös, Herrington & ALOXI
  5	24, 29	Herrstedt, Bös, Hargreaves & Herrington
  6	28	Herrstedt, Bös, Bonadeo & Herrington
  7	21-23, 33-35, 37-39, 43-44, 46-51	Herrstedt, Bös, Bonadeo, Herrington & ALOXI
  8	36, 45	Herrstedt, Bös, Bonadeo, Hargreaves, Herrington & ALOXI

  Core art: Herrstedt & Dombernowsky, Anti-Emetic Therapy in Cancer Chemotherapy, 101 Basic & Clinical Pharmacology & Toxicology 143-150 (2007); Bös et al., U.S. Pat. 6,297,375 B1 (disclosing netupitant as "formula Ib"); Herrington et al. (2008); Hargreaves (NK1 receptor imaging); Bonadeo, WO 2008/049552 (palonosetron soft-gel); and the ALOXI® package insert. Petitioner's theory is that Bös disclosed netupitant itself, and that substituting netupitant for aprepitant in Herrstedt's three-drug antiemetic regimen was obvious — with no unexpected results because "Mere recognition of latent properties in the prior art does not render nonobvious an otherwise known invention" (In re Baxter Travenol).

• Institution decision: Instituted 2025-11-19 (Paper 13, "Decision Granting Institution of Inter Partes Review"). The Board found "Petitioner has shown a reasonable likelihood of establishing that at least claim 1 would have been obvious based on Herrstedt and Bös." Helsinn had moved for discretionary denial; the Board rejected it after the Acting Director referred the discretionary-denial question (see below).

• Final Written Decision: None issued. Claims are neither canceled nor sustained. The statutory deadline under § 316(a)(11) is 2026-11-19 (12 months from institution).

• Settlement / termination: None. The proceeding is live through the merits. Helsinn opposed institution on the merits and on discretion; there is no indication of settlement.

• Appeal: Not yet — an FWD must issue before a § 318 appeal ripens. No Federal Circuit docket exists on this patent.

• Defensive value: This is the petition that matters most, because it attacks independent claim 1 — the broad "regimen of palonosetron, netupitant and dexamethasone" claim that any Akynzeo®-practice theory would rest on. It has cleared institution but not the merits. For a defendant today, this is a "wait for the FWD" situation: a stay motion is now materially stronger than it was before 2025-11-19, but you cannot yet say claim 1 is invalid.

IPR2025-00946 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.

• Type: Inter Partes Review (pre-AIA § 103)

• Filed: 2025-05-01

• Status: Trial Instituted (verbatim: "Instituted"; Google Patents: "Pending - Instituted"). Same posture as -00947.

• Judge panel: Michael J. Fitzpatrick, Sheridan K. Snedden, Christopher G. Paulraj (APJs) — same panel as -00947.

• Petition grounds: The disjoint, non-overlapping half of the patent. Challenges claims 2-4, 11-16, 40-42, and 52-62 (23 claims, including independent claims 2 and 4) under pre-AIA § 103:

  Ground	Claims	Art
  1	2, 3, 4, 11-16, 40, 52-54, 56-62	Herrstedt & Bös
  2	41-42	Herrstedt, Bös & Herrington
  3	(per petition's ground table)	Herrstedt, Bös, Herrington & ALOXI
  4	55	Herrstedt, Bös & Hargreaves

  Independent claim 2 is the "netupitant + a sub-therapeutic dose of dexamethasone" claim; independent claim 4 is the "inducing blood levels of palonosetron and netupitant effective to treat CINV" claim. Petitioner made clear the two petitions were split by claim set, not by strength: "The petitions have been divided to treat claim 1 and its dependencies in the first petition, and to treat claims 2 and 4 and their dependencies in the other," and filed a 37 C.F.R. § 42.4 statement regarding multiple petitions explaining that ranking is "inapplicable" because the claim sets do not overlap.

• Institution decision: Instituted 2025-11-19 (Paper 13, "Decision Granting Institution of Inter Partes Review").

• Final Written Decision: None issued. Statutory FWD deadline 2026-11-19.

• Settlement / termination: None.

• Appeal: Not yet; appeal window only opens on an FWD.

• Defensive value: Independent claims 2 and 4 are the fallback theories a patent owner would pivot to if claim 1 falls. This petition reaches them and was instituted, so a defendant is not left with a "supplemental claim 2/4 theory survives untouched" gap.

Cross-case procedural event affecting both: Director referral on discretionary denial

On 2025-09-19 (Paper 12), the discretionary-denial question across all five Azurity IPRs — IPR2025-00945 (US 8,623,826), IPR2025-00946 ('357), IPR2025-00947 ('357), IPR2025-00948 (US 9,943,515), and IPR2025-00949 (US 10,828,297) — was referred to and decided by Acting Director Coke Morgan Stewart, who held that "discretionary denial of institution is not appropriate in these proceedings." The decision is candid about the tension: "the challenged patents have been in force for several years (2014, 2015, 2018, and 2020), creating strong settled expectations for Patent Owner," and Helsinn had asserted the '357 patent against a generic drug company; but "the parties are not currently engaged in a parallel proceeding involving the challenged patents," and although the grounds "rely on the same or substantially the same art that was considered by the patent examiner," the Director found Azurity "persuasively argues that the data and evidence presented to the patent examiner indicates that the results may not have been unexpected." This is the key precedent-flavored ruling in the chain: the Office declined to use Fintiv-style discretion to protect a long-commercialized Orange Book patent.

Strategic summary

Which claims are CANCELED vs. SUSTAINED vs. UNTESTED. As of 2026-09-17: canceled — none. Sustained — none. Every one of the 62 claims sits in the TESTED-but-undecided bucket: claims 1, 5-10, 17-39, and 43-51 in IPR2025-00947; claims 2-4, 11-16, 40-42, and 52-62 in IPR2025-00946. The two sets are strictly disjoint and together cover claims 1-62 with no overlap and no gaps. There is no claim of the '357 patent that is not under instituted review. So there are no "sustained" claims to build around and no "untested" claims left for a patent owner to retreat to. The court-facing consequence: any argument that "at least the un-challenged claims survive" is unavailable.

Estoppel landscape. No estoppel has attached yet. Section 315(e)(2) estoppel runs from a final written decision, and none has issued in either case. Once the FWDs issue (statutory deadline 2026-11-19), Azurity and its privies will be barred in the parallel litigation from asserting "any ground that the petitioner raised or reasonably could have raised" — which, given the breadth of the two petitions (39 + 23 claims; six prior-art references across eight grounds) and Azurity's practice of filing five coordinated IPRs across four Helsinn patents, is likely to be a broad bar. For a different defendant being asserted against today, no estoppel exists in either direction, and the entire prior-art field (including art Azurity chose not to raise, and art directed at the '357's § 112 written-description/enablement flank, which Azurity did not plead here) remains open. Note also that the § 315(b) one-year bar means any defendant served more than a year ago may already be time-barred from filing its own IPR — it would need to rely on the Azurity proceedings, a stay, or district-court invalidity.

Pattern signals. (i) Not a defensive aggregator. Despite the "Unified Patents PTAB Data" label in the Google Patents metadata (a data-source attribution), the filer is Azurity Pharmaceuticals — a competitor with its own ANDA/commercial interest (Azurity concurrently pursued a PGR against Heron on U.S. 12,115,254 for an aprepitant injectable emulsion). (ii) Same petitioner, five IPRs, four patents — Azurity filed a coordinated package on 2025-05-01: -00945 ('826), -00946 ('357), -00947 ('357), -00948 ('515), and -00949 ('297), covering 49 of what Azurity describes as "133 closely related claims spread over four patents." (iii) Patent owner fights hard. Helsinn retained Paul Hastings (Eric W. Dittmann, Naveen Modi, Isaac S. Ashkenazi, Chetan Bansal) and filed a discretionary-denial request in every case, a full Patent Owner Response in -00947 on 2026-02-25 ("Azurity Fails to Show Motivation to Combine with a Reasonable Expectation of Success"; "Objective Indicia of Nonobviousness"), and a substantial expert record (Exs. 2069, 2070). (iv) No PTAB appeal by Helsinn yet — nothing to appeal. The '357 patent is Orange Book-listed for Akynzeo® (NDA 205718, approved 2014-10-10) with an anticipated expiration of 2030-11-18; a loss here would be a material commercial event, which is why I would expect aggressive briefing and, if the FWD is adverse, a Federal Circuit appeal.

Recommended next steps

• If you are a defendant: the honest answer today is that no claim of 9186357 has been canceled, so there is no dead claim to hang a dispositive motion on yet. What you do have is a very strong stay posture: two instituted IPRs covering all 62 claims, with FWDs due by 2026-11-19. Cite the institution decisions — IPR2025-00946, Paper 13 (2025-11-19) and IPR2025-00947, Paper 13 (2025-11-19) — and the Director's 2025-09-19 discretionary-denial ruling (Paper 12, IPR2025-00945 et al.).
• Trial-stage milestones to calendar: institution 2025-11-19 → Patent Owner Response 2026-02-25 → Petitioner Reply (~2026-05) → Oral hearing (~2026-08/09) → FWD due no later than 2026-11-19 (statutory one-year clock, § 316(a)(11)). If the FWD cancels claim 1, re-check your infringement contentions immediately; if it sustains claim 1, evaluate a Rebeck-style "substantial new question of patentability" request or a design-around, because Azurity's ground set will then be estopped.
• Where the case is likely to turn: Helsinn's opposition is not a technical-claim-construction defense — it is a motivation-to-combine + reasonable-expectation-of-success + objective-indicia fight. Helsinn concedes Bös discloses netupitant and instead argues (a) a POSA in Nov 2009 had many non-netupitant pathways (olanzapine, gabapentin, cannabinoids as a fourth drug), and (b) aprepitant-based triple therapy did not control nausea, so there was no expectation that swapping in netupitant would. Its strongest weapon is the FDA-approved rule 132 synergy data that persuaded the examiner. Azurity's counter — that the Rule 132 table was selectively edited and that palonosetron + any NK1 antagonist works — is the factual crux. If you are a defendant, that dataset dispute is also fertile ground for a district-court inequitable-conduct theory.
• Two verification gaps I could not close and would not assert either way: (1) whether the 2025-11-19 institution decisions instituted on all challenged claims/grounds or only a subset — the public snippets confirm institution and an RLP finding "at least [as to] claim 1," but not the claim-by-claim scope; pull the full Papers 13 from PTAB E2E to confirm. (2) The Google Patents litigation block lists New Jersey District Court cases 3:22-cv-04635 and 2:22-cv-04635, yet the Director's September 2025 decision states "the parties are not currently engaged in a parallel proceeding involving the challenged patents." Those two facts may not conflict (different parties, different patents, or a resolved case), but I cannot reconcile them from the available record — treat the parallel-litigation status as unresolved.

Bottom line for a defendant: the patent is not hardened and not dead — it is under maximal attack. All 62 claims are in instituted IPR, the Office refused to discretionarily deny, and a merits ruling is imminent (by 2026-11-19). Do not assume claim 1 is unenforceable, and do not concede it is bulletproof. The next ~60 days will decide which.

I'll research the assignment records and related litigation/ownership context before building the report.

Let me dig into the specific assignment records, correspondents, and Helsinn ownership context.

Let me search for the specific assignment database records and litigation timing details.

Ownership & Assignment Analysis — US 9,186,357 B2

Data-availability caveat (read first): I was able to retrieve the dates, conveyance types, and parties of the recorded post-issuance events from Google Patents' legal-events feed (which mirrors the USPTO assignment record) and to cross-check the litigation/PTAB history. I was not able to retrieve the reel/frame numbers or the correspondent of record (recording attorney/firm) for any of the three events — those fields are not exposed in the sources reachable with the tools available for this task, and the USPTO Assignment Center itself was not directly queryable. Those fields are marked as data gaps below rather than guessed. Nothing in this report is fabricated; where the record is silent, I say so.

Inventors

All five named inventors are Helsinn personnel (the application was filed and assigned to Helsinn Healthcare SA, Pazzallo, Switzerland). Specific employing entity is not established on the patent face.

Unusual pattern worth flagging: the recorded 2015-02-04 assignment lists a sixth assignor — Riccardo Braglia — who is NOT a named inventor on the '357 patent. Braglia is the founder/principal of the Helsinn group. This is most consistent with a single assignment instrument covering multiple applications/patents in the family (Braglia being an inventor on a sibling case) rather than any inventorship defect, but it is a documentary mismatch a diligence reviewer should resolve against the underlying assignment document.

No evidence of inventors departing the original assignee, and no fire-sale precursor pattern. All inventors remain associated with a still-operating assignee.

Original assignee

• Entity: Helsinn Healthcare SA (Switzerland) — named on the issued patent and current assignee.
• Business: Specialty pharmaceutical company (oncology supportive care, pain/inflammation, GI), founded 1976 by Gabriele Braglia; parent of the Helsinn Group, with subsidiaries Helsinn Birex Pharmaceuticals Ltd. (Ireland), Helsinn Therapeutics (U.S.), Inc. (Iselin, NJ), and Helsinn Pharmaceuticals (Beijing).
• Product embodying the claims: Yes. The '357 patent is listed in the Orange Book against AKYNZEO (netupitant + palonosetron HCl), NDA 205718, FDA-approved 2014-10-10, and against AKYNZEO for Injection (fosnetupitant/palonosetron), NDA 210493, approved 2018-04-19. Orange Book expiry for '357 is 2030-11-18 (use codes U-2293 / U-2301 / U-528 depending on the listing).
• Status: Operating. Helsinn is actively commercializing Akynzeo and enforcing the '357 patent (see litigation below). No bankruptcy or dissolution identified.

This is the single most important fact for the verdict: the current assignee ships a commercial product covered by the patent.

Assignment timeline

Three post-issuance events are recorded. Reel/frame and correspondent fields were not retrievable and are shown as open fields.

• 2015-02-04 (executed/recorded) — Reel not retrieved

  • Conveyance: Assignment
  • Assignor: Bonadeo, Daniele; Braglia, Riccardo; Cannella, Roberta; Cantoreggi, Sergio; Rossi, Giorgia; Trento, Fabio
  • Assignee: Helsinn Healthcare SA
  • Correspondent: not retrieved (data gap)
  • Context: Routine inventor→company assignment perfecting title in the original assignee; captures the application/patent plus family members.

• 2022-12-30 (executed/recorded) — Reel not retrieved

  • Conveyance: Security Interest (grant of security)
  • Assignor/Grantors: Helsinn Birex Pharmaceuticals Limited; Helsinn Healthcare SA; Helsinn Therapeutics (U.S.), Inc.
  • Assignee/Secured party: Hamilton SA LLC
  • Correspondent: not retrieved (data gap)
  • Context: Securitization / secured financing — a blanket IP collateral grant by the three Helsinn operating entities to a single collateral agent, not a sale or an NPE transfer. The multi-grantor/single-agent structure is the signature of a credit facility, not an assertion vehicle.

• 2023-09-20 (executed/recorded) — Reel not retrieved

  • Conveyance: Release by Secured Party
  • Assignor: Hamilton SA LLC
  • Assignee/Released parties: Helsinn Healthcare SA; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
  • Correspondent: not retrieved (data gap)
  • Context: Termination of the security interest — full title reverts to (and remains with) the Helsinn operating entities. Net effect of the chain: no change in ultimate ownership; Helsinn Healthcare SA is still the assignee of record.

Because only three events are recorded and the last one restores the status quo, the patent has never left Helsinn control.

Timeline diagram

timeline
    title Ownership of US 9186357
    2009 : Priority date Nov 18
    2013 : Application filed Nov 1
    2015 : Patent granted Nov 17
         : Inventors assign rights to Helsinn
    2022 : Helsinn sues Gland Pharma in New Jersey
         : Hamilton SA LLC records security interest
    2023 : Security interest released back to Helsinn
    2025 : Azurity files IPRs against the patent

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. The only "transfer" in the chain is a security interest recorded 2022-12-30, not a conveyance of title to a licensing LLC, and it was released 2023-09-20. Hamilton SA LLC appears as a secured party/collateral agent for a multi-entity grantor group — a lender role, not a shell-owner role. Naming alone is not evidence; the security-interest and release conveyances affirmatively establish this is financing, not a shell transfer.

2. Known asserter in the chain — Not present. No assignee matches any public NPE list (Acacia, Marathon, IV, IPNav, Wi-LAN, Conversant/Mosaid, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Spangenberg entities, etc.). The chain is Helsinn → (security interest) → Helsinn, with a lender in between.

3. Repeat correspondent across the chain — Insufficient data. The correspondent of record for each of the three recordations could not be retrieved with available tools (see caveat). With only three events — two of which are a matched security-interest/release pair — recurrence would not be expected in any event. Cannot make the call.

4. Cascading transfers — Not present. Only one non-ownership event plus its reversal, ~9 months apart (2022-12-30 → 2023-09-20), involving the same grantor group and the same counterparty. No chained LLCs, no shared correspondent addresses observed.

5. Pre-litigation transfer — Not present. The first infringement suit (Helsinn Healthcare S.A. v. Gland Pharma Ltd., D.N.J., Case No. 2:22-cv-04635 / 3:22-cv-04635, filed 2022-07-18, terminated 2022-12-23) precedes the security interest (2022-12-30), which is itself not an ownership transfer. There is no assignment "arranged to enable assertion" — Helsinn asserted as the pre-existing owner.

6. Bankruptcy fire-sale — Not present. No Chapter 7/11 proceeding or patent-sale process involving Helsinn identified. The assignee is solvent and operating.

7. Privateering — Not present. Helsinn asserts the '357 patent on its own behalf as the operating manufacturer/marketer of Akynzeo; there is no transfer to a proxy NPE asserting for Helsinn against competitors.

8. Defensive aggregator (anti-NPE) — Not present. The chain does not terminate at RPX, AST, LOT, Unified, or OIN.

Additional operating-company evidence (context, not an NPE signal): Helsinn is a serial ANDA enforcer on this product — the '357 patent was asserted against Gland Pharma in the July 2022 New Jersey action (one of ten patents-in-suit), and is the subject of two Azurity Pharmaceuticals IPRs, IPR2025-00946 and IPR2025-00947, both filed 2025-05-01 and reported as instituted. Helsinn also filed a discretionary-denial request on the related '515 patent. This is the enforcement profile of a branded manufacturer, the opposite of an aggregator. (The Google Patents record also lists first worldwide family litigation for family 45806930, and two D.N.J. docket entries — 3:22-cv-04635 and 2:22-cv-04635 — reflecting the same Gland Pharma action.)

Verdict

Operating-company assertion.

Helsinn Healthcare SA is the assignee of record throughout — the 2022-12-30 grant to Hamilton SA LLC was a security interest only and was extinguished by the 2023-09-20 release by secured party, leaving title with the three Helsinn operating entities. Helsinn ships a product embodying the claims (AKYNZEO, NDA 205718, approved 2014-10-10; AKYNZEO for Injection, NDA 210493) and enforces the patent directly against generic ANDA filers (Helsinn v. Gland Pharma, D.N.J., filed 2022-07-18) and defends it at the PTAB (Azurity IPR2025-00946/00947, filed 2025-05-01). No shell-entity, known-asserter, cascading-transfer, pre-litigation-transfer, bankruptcy, or privateering signal is present; the correspondent signal is unassessable due to a data gap.

Verification links:

• USPTO Assignment Center (search "9186357"): https://assignmentcenter.uspto.gov/
• Google Patents legal events for this patent: https://patents.google.com/patent/[US9186357B2](/patent/US9186357B2)
• D.N.J. action (Gland Pharma): https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/2%3A22-cv-04635
• PTAB IPR2025-00946: https://portal.unifiedpatents.com/ptab/case/IPR2025-00946

Open items to close with a direct Assignment Center pull: reel/frame for all three events; correspondent of record on each; and confirmation whether the 2015 assignment instrument also covered sibling family members (which would explain the Riccardo Braglia assignor entry).

I'll research US patent 9186357 and its prior art citations.

Let me gather the specific citation lists for this patent from the USPTO/FPO records.

Let me confirm the exact front-page reference list for this patent.

Prior-Art Analysis — US 9,186,357 B2

1. Patent identification (literal)

Source: https://patents.google.com/patent/US9186357/en

Important caveat on methodology. I could not retrieve the actual USPTO PatentCenter front-page "(56) References Cited" image in this session. The list below is compiled from the Google Patents, PubChem, and FreePatentsOnline records, which agree on the following patent documents cited. The patent's own front page distinguishes (a) references cited by the applicant in the specification (mostly Helsinn's underlying compound and formulation patents) from (b) references cited by the examiner. Where I could not verify a reference's subject matter with high confidence, I say so explicitly rather than guess.

Critical legal note: Because the effective priority date is 2009-11-18, this is a pre-AIA patent, so 35 U.S.C. § 102(a)/(b)/(e) governs. A reference named on the face of a patent is not, by that fact alone, § 102 prior art — several of these are the patentee's own earlier patents and family members (which are prior art only against the claims, not the specification, under limited circumstances). I flag which ones are the patentee's own.

2. Patent citations on the face of US 9,186,357

A. Palonosetron-related references (relevant to the palonosetron element of claims 1, 4, and to dependent claims)

1. US 5,202,333 A — Palonosetron / hexahydro-1H-benz[de]isoquinoline compounds (Helsinn/Beecham lineage)

• Cited in the specification as a synthesis reference for palonosetron.
• Claim exposure under §102: Could anticipate the palonosetron compound element of claims 1 and 4, but does not disclose netupitant or dexamethasone, so it cannot anticipate any claim as a whole. Relevant only as § 102(a) art for the palonosetron moiety.
• Confidence in exact title/date: moderate; I did not independently verify the issue date.

2. US 5,510,486 A — Palonosetron synthesis

• Cited alongside the above as a method-of-synthesis reference.
• Claim exposure: Same as above — palonosetron moiety only; no netupitant/dexamethasone.

3. WO 2004/045615 A1 — Helsinn Healthcare — "Palonosetron for the treatment of chemotherapy-induced emesis"

• Published 2004-06-03 (per Google Patents family listing).
• Claim exposure under §102: Discloses palonosetron for CINV. This is the closest face-cited reference to the palonosetron/treating-CINV element of claims 1 and 4 and the "chemotherapy" limitations of claims 5–10. It does not disclose the netupitant + dexamethasone combination, so no complete anticipation.

4. WO 2004/073714 A1 — Helsinn Healthcare — palonosetron (dosage/use)

• Cited as a source for palonosetron dosage forms.
• Claim exposure: Palonosetron element only; supports obviousness (not anticipation) of the combination.

5. WO 2004/067005 A1 — Helsinn Healthcare — palonosetron pharmaceutical dosage forms

• Claim exposure under §102: Potentially relevant to the dosage-form/soft-gel limitations of claims 19–28 (unit dosage form, palonosetron soft-gel), but discloses no netupitant co-formulation.

6. WO 2008/049552 A1 — Helsinn Healthcare — "Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability"

• Published 2008-05-02.
• Claim exposure under §102: This is the most directly material face-cited reference to the formulation claims. It discloses the palonosetron soft-gel capsule and the degraded-by-product issue, which map to the "(3S)-3-[(3aS)-1-oxo-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinoline-2-yl]-1-azoniabicyclo[2.2.2]octan-1-olate" limitations (claim 19 et seq.; see claim 28). It does not disclose netupitant, so it cannot anticipate a combination claim.

B. Netupitant-related references (relevant to the netupitant element of claims 1, 2, 4)

7. US 6,297,375 B1 — Hoffmann-La Roche — Netupitant and prodrugs

• Cited in the specification: "Methods of synthesizing and formulating netupitant and its prodrugs are described in U.S. Pat. Nos. 6,297,375, 6,719,996 and 6,593,472."
• Claim exposure under §102: Discloses the netupitant compound and its formulations. Anticipates the netupitant element only; discloses no palonosetron or dexamethasone combination.

8. US 6,593,472 B2 — Hoffmann-La Roche — netupitant prodrugs (incl. N-oxide of netupitant)

• Claim exposure: Netupitant/prodrug element; relevant to claim 4 (inducing netupitant blood levels) and prodrug-dependent variations. No combination disclosure.

9. US 6,719,996 B2 — Hoffmann-La Roche — netupitant (synthesis/formulation)

• Claim exposure: Netupitant element only.

C. Unverified / I could not confirm the subject matter

10. WO 2007/096763 A2 — I could not verify the assignee or subject matter with high confidence in this session. It appears in the Google Patents citation list but I did not retrieve its content. It should be checked directly in PatentCenter before being relied on.

11. US 2009/0036459 A1 — I could not confirm the subject matter (title/assignee) with high confidence. Verify directly.

12. JP 2009-507933 A — Appears to be a Japanese national-phase publication of a PCT (likely a palonosetron- or NK1-related Helsinn/Roche family member). Subject matter not verified here.

3. Which face-cited patent references could anticipate (as opposed to support obviousness)

Applying § 102 strictly — a single reference must disclose every limitation of a claim:

Bottom line on the face citations: The patent-document citations are essentially the patentee's own (palonosetron) plus Hoffmann-La Roche's (netupitant) underlying compound/formulation patents. None individually anticipates the claimed combinations; they are best characterized as § 103 art (or as background/enablement citations), not § 102 anticipatory art, for the independent combination claims.

4. The genuinely most relevant prior art (per the live IPR record)

The pending instituted IPRs identify the references that actually matter for the combination claims. From the PTAB petition record (IPR2025-00946 / -00947), the applied references — all characterized as 35 U.S.C. § 102(b) prior art (publicly available over one year before the critical date) — are the non-patent literature and the FDA aprepitant labeling, including:

• Herrstedt (2007) — review of CINV therapy; teaches adding an NK₁ antagonist (e.g., aprepitant) to a 5-HT₃ antagonist + corticosteroid (dexamethasone) combination; discusses palonosetron.
• Grunberg et al., Support Care Cancer (2009) 17:589–594 — single-day three-drug regimen of dexamethasone + palonosetron + aprepitant for MEC-induced CINV. Most relevant to the triple-combination claims (1, 4).
• Warr et al., J. Clin. Oncol. (2005) 23(12):2822–2830 — aprepitant for CINV after MEC.
• Herrington et al., Cancer (2008) 112(9):2080–2087 — single-dose aprepitant + palonosetron + dexamethasone for acute/delayed CINV. Highly relevant to claims 1/4.
• Yeo et al., Breast Cancer Res. Treat. (2009) 113:529–535 — aprepitant + ondansetron + dexamethasone for CINV.
• Longo et al., Support Care Cancer (2011) 19:1159–1164 — palonosetron + 3-day aprepitant + dexamethasone for HEC.
• De Wit, Br. J. Cancer (2003) 88(12):1823–1827; Diemunsch et al. (2003 and 2009); Ruhlmann et al. (2009); Pellegatti et al. (2009); Huang et al., Expert Opin. Ther. Patents (2010) 20(8):1019–1045; FDA-approved Emend® (aprepitant) labeling (2003).
• Press releases: GSK (Zunrisa/Rezonic update, 2009-09-28); Roche NK₁ antagonist (2006-02-23).

These NPL references are the ones that (i) disclose the triple-drug class combination for CINV and (ii) were placed in the § 102(b) category by the petitioner — i.e., they are the strongest anticipation/obviousness candidates for claims 1–18. Whether any single one discloses netupitant specifically (as opposed to aprepitant) is the pivotal § 102 question; the petition appears to rely on the "NK₁ antagonist" genus reading plus inherent properties for netupitant.

5. Honest limits of this analysis

1. I did not pull the actual USPTO PatentCenter "(56)" front-page image; the citation list above is triangulated from Google Patents, PubChem, and FPO.
2. Three citations (WO 2007/096763, US 2009/0036459, JP 2009-507933) are listed but their content was not verified in this session — do not rely on them without checking PatentCenter.
3. I did not obtain the exact issue/filing dates for US 5,202,333 / 5,510,486 / 6,297,375 / 6,593,472 / 6,719,996 individually; treat those dates as unverified here.
4. Full anticipation charting (element-by-element) requires the actual claim text of all 62 claims and the full reference texts; the claim mapping above is preliminary.

Recommendation: For a defensible § 102 analysis, retrieve (a) the USPTO PatentCenter front page and file wrapper for 14/069,927, and (b) the complete petition papers for IPR2025-00946 and IPR2025-00947, which contain the element-by-element claim charts the user is ultimately seeking.

I'll research the prior art cited on the US9186357 page and related references before analyzing obviousness.

I have strong results. Let me pin down the specific prior-art reference identities cited in the IPR petitions and the patent's own citation record.

Obviousness Analysis — U.S. Patent 9,186,357 B2

"Compositions and methods for treating centrally mediated nausea and vomiting" (Helsinn Healthcare SA)

Prepared: April 26, 2026 | Effective filing date: 2009‑11‑18 (PCT/IB2010/003106 priority; appl. 14/069,927 filed 2013‑11‑01) | Grant: 2015‑11‑17

1. Governing law and framework

Because the effective filing date (2009‑11‑18) predates March 16, 2013, the pre‑AIA version of 35 U.S.C. § 103(a) governs, and the references below were assessed as § 102(b) art (all published/issued more than one year before the critical date). The controlling standard is KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007): a combination is obvious where the prior art teaches or suggests the claimed elements, the elements are arranged as taught, and there is a reason to combine plus a reasonable expectation of success. Substitution of one known element for another to obtain a predictable result, and "obvious to try" variations on a known, finite set of identified solutions, are expressly within § 103.

⚠️ Note on the PTAB entries. The Google Patents page (https://patents.google.com/patent/US9186357/en) lists IPR2025‑00946 and IPR2025‑00947 (Pending – Instituted), with the petitioner field showing only the data-provider attribution ("Unified Patents PTAB Data"). The filed petitions themselves name Azurity Pharmaceuticals, Inc. as petitioner (see https://paragraphfour.com/wp-content/uploads/2025/05/ipr25-0947P.pdf and the USPTO PTACTS documents). I report both, taking the petitions as the operative record.

2. The claimed subject matter

The '357 patent issued with 62 claims (the Google Patents copy reproduced here truncates after claim 16; further text appears in secondary sources such as DrugPatentWatch). The independent claims, in substance:

3. Prior art of record (patent citations + IPR‑asserted art)

The page's "Prior art keywords" are chemotherapy, netupitant, cinv, dose, palonosetron — i.e., the Examiner's own framing already treated netupitant dosing for CINV as the core.

A. Netupitant / NK₁ chemistry (in the patent's own "Background"):

• U.S. Pat. Nos. 6,297,375; 6,719,996; 6,593,472 (Hoffmann‑La Roche) — synthesis/formulation of netupitant and its prodrugs (expressly incorporated by reference in the '357 specification).
• Bös et al., "4‑phenyl‑pyridine derivatives," U.S. 6,297,375 B1 (issued 2 Oct. 2001) (IPR EX1014; related US 6,479,483 B2, https://patentimages.storage.googleapis.com/c4/93/94/53fdfe1106e56e/US6479483.pdf) — discloses netupitant ("formula Ib") as a potent, selective, orally active NK₁ antagonist, expressly for emesis; teaches oral daily dosing of ~10–1000 mg; reports a long half‑life (~24–30 h).
• T. Hoffmann et al., 16 Bioorg. Med. Chem. Lett. 1362–1365 (2006) (EX1011) — netupitant is potent, selective, orally active, with good CNS penetration.
• Huang et al., Expert Opin. Ther. Patents 20(8):1019–1045 (2010) — NK₁ antagonist survey (cited/alluded to in the '357 specification).

B. 5‑HT₃ antagonist / palonosetron (in the specification):

• WO 2004/045615; WO 2004/073714; WO 2004/067005; WO 2008/049552 (Helsinn) — palonosetron and its oral soft‑gel dosage forms (WO 2008/049552 incorporated by reference for the soft‑gel capsule).
• U.S. 5,202,333; 5,510,486 — palonosetron synthesis.
• ALOXI® label (EX1015) — approved palonosetron doses (0.25 mg IV; 0.5 mg oral).
• Bonadeo (EX1017) — palonosetron oral/soft‑gel formulation with oxygen‑protection against degradation (family of WO 2008/049552/US 8,426,450; Daniele Bonadeo is a co‑inventor of the '357 patent itself). (Exact number not confirmed from the sources retrieved — flagged.)

C. Triple‑therapy / dosing‑regimen art:

• J. Herrstedt & P. Dombernowsky, "Anti‑Emetic Therapy in Cancer Chemotherapy: Current Status," 101 Basic & Clin. Pharmacol. & Toxicol. 143–150 (2007) (EX1010) — teaches the NK₁ antagonist + 5‑HT₃ antagonist + dexamethasone triple regimen; palonosetron as an improved, long‑acting (t½ ≈ 40 h) 5‑HT₃ antagonist effective in delayed emesis; and that aprepitant roughly doubles dexamethasone AUC via CYP inhibition.
• MASCC guidelines (EX1013) — triple therapy is the recommended standard of care for HEC (acute and delayed), and that dexamethasone is dose‑reduced when co‑given with an NK₁ antagonist because of the ~2‑fold exposure increase.
• Herrington et al., Cancer 112(9):2080–2087 (2008) (EX1016; https://pubmed.ncbi.nlm.nih.gov/18327813/) — aprepitant single 125 mg day‑1 dose plus palonosetron 0.25 mg IV and dexamethasone 12 mg day 1 / 8 mg days 2–4 is as effective as 3‑day aprepitant for acute and delayed emesis (93% emesis‑free, days 1–5).
• R. Hargreaves, 63(11) J. Clin. Psychiatry (2002) (EX1012) — PET imaging of NK₁ receptor occupancy in the human brain.
• Grunberg et al., Support Care Cancer 17:589–594 (2009); Ruhlmann et al., Ther. Clin. Risk Manag. 2009:5 375–384; Pellegatti et al., Drug Metab. Dispos. 37(8):1635–1645 (2009) — cited in the '357 Background on aprepitant/casopitant nausea performance.

4. The combinations and the motivation to combine

Ground 1 — Herrstedt + Bös ⇒ Claims 1, 5–10, 17

Herrstedt supplies every element of the claimed regimen except the identity of the NK₁ antagonist: a triple regimen of a 5‑HT₃ antagonist (expressly including palonosetron), an NK₁ antagonist (aprepitant), and dexamethasone for CINV. Bös supplies netupitant as an NK₁ antagonist in the same class, acting through the same mechanism (NK₁ antagonism) for the same purpose (emesis).

• Motivation: Substituting a newer, potent, selective, orally active member of a known class for the class member already in the regimen is the paradigmatic KSR substitution ("one known element for another to obtain predictable results"). Bös and Hoffmann independently flag netupitant's potency, oral activity, CNS penetration and long half‑life — exactly the properties that make an NK₁ antagonist favorable in a once‑daily antiemetic.
• Reasonable expectation of success: Same target, same therapeutic goal; netupitant had already blocked emesis in ferret/Suncus models (Bös).
• The Board agreed at institution, finding "a reasonable likelihood … that at least claim 1 would have been obvious based on Herrstedt and Bös" (https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1557833](/patent/1557833)/...).

Ground 2 — Herrstedt + Bös + Herrington ⇒ Claims 2–3, 18–19, 25–27, 30–32

Herrington converts the "regimen" into a single‑dose, 5‑day‑effective protocol, and supplies the exact dexamethasone taper (12 mg / 8 mg / 8 mg / 8 mg) with palonosetron. The MASCC guidance (EX1013) supplies the motivation to reduce the steroid dose when an NK₁ antagonist is co‑administered (the aprepitant ~2‑fold dexamethasone exposure increase), which is the express rationale of claims 2 and 3: Herrington's 12 mg is 60% of the 20 mg minimum effective day‑1 dexamethasone dose of Jordan et al. (The Oncologist 12(9):1143–1150 (2007)) — squarely inside the claimed 50–70% window.

• Motivation: Patient convenience, reduced steroid burden, avoiding a second dose once the NK₁ antagonist's long half‑life sustains receptor blockade. A POSA would reasonably expect Bös' netupitant (t½ 24–30 h) to mirror the single‑dose sufficiency Herrington demonstrated for aprepitant.

Ground 3 — + ALOXI ⇒ Claim 20 (200–400 mg netupitant; 0.25–0.75 mg oral palonosetron)

Bös teaches 10–1000 mg oral netupitant; the ALOXI label teaches 0.25 mg IV / 0.5 mg oral palonosetron. Selecting 200–400 mg and 0.25–0.75 mg is routine optimization of a result‑effective variable (In re Urbanski, 809 F.3d 1237 (Fed. Cir. 2016)).

Ground 5 / 8 — + Hargreaves ⇒ Claims 24, 29, 36, 45 (≥70% striatum occupancy at 96 h)

Hargreaves establishes that NK₁ receptor occupancy can be measured by PET and that NK₁ antagonists prevent acute and delayed CINV; Bös establishes netupitant's long half‑life. The claimed occupancy is a latent property of a known compound administered at an obvious dose — "mere recognition of latent properties in the prior art does not render nonobvious an otherwise known invention," In re Baxter Travenol, 952 F.2d 388, 392 (Fed. Cir. 1991). The specification's own FIG. 5 data confirm rather than create the property.

Ground 6 / 7 — + Bonadeo (+ Herrington, ALOXI) ⇒ Claims 21–23, 28, 33–35, 37–39, 43–44, 46–51

• Claim 28 (degradant "substantially absent"): Bonadeo teaches palonosetron formulations stabilized against oxygen‑mediated degradation — i.e., the by‑product recited in claim 28 is the very degradation species Bonadeo addresses.
• Fixed‑combination / single unit‑dose claims (21–23): where prior art drugs are co‑prescribed in close temporal proximity (Herrstedt/Herrington), there is a recognized "considerable practical advantage in giving the required drugs in single formulation" — greater convenience, safety, and reduced medication error. This is the fact pattern of Richardson‑Vicks Inc. v. Upjohn Co., 122 F.3d 1476, 1480–83 (Fed. Cir. 1997) (single‑unit dosage of separately‑prescribed drugs obvious as a matter of law, regardless of synergy evidence). Double‑capsule/fixed combinations of two actives were well‑known in the art.

Claim 4 (blood levels effective to treat CINV)

The prosecution record shows the applicants tied the "blood levels" limitation to Table 5 of the specification, which attributes efficacy to administered doses, not measured plasma concentrations. If the doses are obvious, a limitation expressed as the therapeutically effective blood level the dose produces is likewise obvious.

5. Secondary considerations / patentability rebuttal

The Examiner allowed the claims on evidence of "synergy (unexpected result) from the combination of netupitant and palonosetron," relying on a Rule 132 declaration (see IPR2025‑00946/947 record). Petitioners attack this on three fronts, each material to the § 103 calculus:

1. No unexpected result over the closest art — the comparison that matters is netupitant‑palonosetron vs. the aprepitant‑palonosetron regimen of Grunberg/Herrington, and the "no nausea"/"no significant nausea" figures for netupitant‑palonosetron are close to those of aprepitant‑palonosetron (per the Board's institution order discussion of the mischaracterization arguments).
2. No adequate nexus / no defined synergy — synergy was neither defined with specificity nor tied to the claimed scope.
3. Latent‑property problem — the specification's "unexpected" properties (single‑dose 5‑day efficacy, acute‑phase benefit, CNS occupancy) are properties of netupitant, a prior‑art compound, so their mere recognition cannot confer patentability (Baxter Travenol).

If the Patent Owner cannot establish a statistically and clinically robust, art‑displacing difference with a nexus to the claims, the KSR combination stands and claims 1–62 are invalid under § 103.

6. Bottom line and caveats

• Strongest obviousness case: Herrstedt + Bös for claims 1, 5–10, 17; + Herrington for the single‑dose/timing and 12 mg dexamethasone limitations (claims 2–3, 18–19, 25–27, 30–32); + ALOXI/Bonadeo/Hargreaves for the dose, formulation, unit‑dose, and receptor‑occupancy dependent claims.
• Motivation to combine is twofold: (i) class substitution — swap the known NK₁ antagonist (aprepitant) for another potent, orally active NK₁ antagonist (netupitant) with a predictable same‑mechanism result; and (ii) regimen simplification — Herrington/MASCC establish single‑dosing and steroid dose‑reduction as the accepted objective.
• PTAB posture: both IPR2025‑00946 and IPR2025‑00947 were instituted (Pending – Instituted per the Google Patents page); the Board found a reasonable likelihood of unpatentability of at least claim 1 over Herrstedt + Bös.

Caveats (per operating rules — no fabrication):

• The '357 Google Patents page truncates the claim set at claim 16; I reconstructed claims 19–51 from a secondary source (DrugPatentWatch) and have not independently verified the complete, verbatim claim set.
• I have not confirmed the exact patent number for the "Bonadeo" reference (EX1017); it is described in the record as a palonosetron dosage‑form patent in the WO 2008/049552 / US 8,426,450 family, but the identifier is unverified.
• Reference identities and characterizations for the IPR‑asserted art (EX1010–EX1017) are drawn from the petitions and petitions' expert declaration (EX1009), i.e., an advocacy record; I have not independently read the full texts of every exhibit.
• The Google Patents page labels the PTAB petitioner field as "Unified Patents PTAB Data"; the petitions themselves name Azurity Pharmaceuticals, Inc. as petitioner.

Primary sources: https://patents.google.com/patent/US9186357/en · https://paragraphfour.com/wp-content/uploads/2025/05/ipr25-0947P.pdf · https://ptacts.uspto.gov/ptacts/public-informations/petitions/1557833/ · https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1557834](/patent/1557834)/ · https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1557835](/patent/1557835)/ · https://pubmed.ncbi.nlm.nih.gov/18327813/ · https://patentimages.storage.googleapis.com/c4/93/94/53fdfe1106e56e/US6479483.pdf · https://portal.unifiedpatents.com/ptab/case/IPR2025-00946 · https://portal.unifiedpatents.com/ptab/case/IPR2025-00947